I-Tech AB (ITECH.ST)
SEK 54.5
(-1.8%)
SEK 54.5
(-1.8%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 24.43 Million SEK | 103.22% |
| 2022 | 12.02 Million SEK | 477.76% |
| 2021 | -3.18 Million SEK | 44.61% |
| 2020 | -5.74 Million SEK | 17.11% |
| 2019 | -6.93 Million SEK | 49.12% |
| 2018 | -13.62 Million SEK | -82.94% |
| 2017 | -7.44 Million SEK | -9.0% |
| 2016 | -6.83 Million SEK | 16.91% |
| 2015 | -8.22 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 10.9 Million SEK | 19.19% |
| 2024 Q3 | 9.43 Million SEK | -13.45% |
| 2024 Q1 | 9.14 Million SEK | 1279.64% |
| 2023 Q1 | 8.34 Million SEK | 54.0% |
| 2023 FY | 24.43 Million SEK | 103.22% |
| 2023 Q4 | 663 Thousand SEK | -91.85% |
| 2023 Q3 | 8.13 Million SEK | 10.07% |
| 2023 Q2 | 7.38 Million SEK | -11.49% |
| 2022 Q1 | 649 Thousand SEK | 127.2% |
| 2022 FY | 12.02 Million SEK | 477.76% |
| 2022 Q4 | 5.42 Million SEK | 12.87% |
| 2022 Q3 | 4.8 Million SEK | 226.89% |
| 2022 Q2 | 1.46 Million SEK | 126.35% |
| 2021 Q1 | 58 Thousand SEK | 101.65% |
| 2021 Q3 | 837 Thousand SEK | 126.22% |
| 2021 Q4 | -2.38 Million SEK | -385.07% |
| 2021 FY | -3.18 Million SEK | 44.61% |
| 2021 Q2 | -3.19 Million SEK | -5603.45% |
| 2020 Q4 | -3.5 Million SEK | -385.06% |
| 2020 Q3 | -723 Thousand SEK | -1638.3% |
| 2020 Q1 | -984 Thousand SEK | -7.54% |
| 2020 FY | -5.74 Million SEK | 17.11% |
| 2020 Q2 | 47 Thousand SEK | 104.78% |
| 2019 Q2 | -906 Thousand SEK | 79.57% |
| 2019 FY | -6.93 Million SEK | 49.12% |
| 2019 Q4 | -915 Thousand SEK | -19.92% |
| 2019 Q3 | -763 Thousand SEK | 15.78% |
| 2019 Q1 | -4.43 Million SEK | -53.89% |
| 2018 Q2 | -2.54 Million SEK | 22.79% |
| 2018 FY | -13.62 Million SEK | -82.94% |
| 2018 Q3 | -4.89 Million SEK | -92.57% |
| 2018 Q1 | -3.29 Million SEK | -59.87% |
| 2018 Q4 | -2.88 Million SEK | 41.17% |
| 2017 Q3 | -1.67 Million SEK | -37.89% |
| 2017 Q1 | -2.49 Million SEK | 0.0% |
| 2017 Q2 | -1.21 Million SEK | 51.4% |
| 2017 Q4 | -2.06 Million SEK | -23.12% |
| 2017 FY | -7.44 Million SEK | -9.0% |
| 2016 FY | -6.83 Million SEK | 16.91% |
| 2015 FY | -8.22 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 109.814% |
| Ziccum AB (publ) | -21.56 Million SEK | 213.335% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 248.985% |
| BioArctic AB (publ) | 252.64 Million SEK | 90.328% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | 2991.716% |
| Mendus AB (publ) | -100.65 Million SEK | 124.277% |
| Genovis AB (publ.) | 54.22 Million SEK | 54.937% |
| Intervacc AB (publ) | -93.57 Million SEK | 126.112% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | 257.523% |
| Active Biotech AB (publ) | -46.48 Million SEK | 152.566% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | -35.682% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 144.093% |
| Aptahem AB (publ) | -10.1 Million SEK | 341.817% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 107.6% |
| Kancera AB (publ) | -65.04 Million SEK | 137.568% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 118.151% |
| Fluicell AB (publ) | -26.87 Million SEK | 190.907% |
| Saniona AB (publ) | -81.06 Million SEK | 130.142% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | 297.518% |
| Biovica International AB (publ) | -126.07 Million SEK | 119.382% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 157.487% |
| AcouSort AB (publ) | -17.48 Million SEK | 239.732% |
| Xintela AB (publ) | -57.23 Million SEK | 142.69% |
| Abliva AB (publ) | -96.54 Million SEK | 125.309% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 107.523% |
| Karolinska Development AB (publ) | -3.5 Million SEK | 797.147% |
| OncoZenge AB (publ) | -15.9 Million SEK | 253.66% |
| Amniotics AB (publ) | -29.07 Million SEK | 184.047% |
| 2cureX AB (publ) | -36.36 Million SEK | 167.197% |
| CombiGene AB (publ) | -36.3 Million SEK | 167.304% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | 266.906% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 106.357% |
| Camurus AB (publ) | 532.35 Million SEK | 95.41% |
| Corline Biomedical AB | -1.78 Million SEK | 1466.611% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 113.518% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 158.621% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 103.099% |
| Cyxone AB (publ) | -21.66 Million SEK | 212.806% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 123.06% |
| Biosergen AB | -27.26 Million SEK | 189.62% |
| Cantargia AB (publ) | -290.01 Million SEK | 108.425% |
| NextCell Pharma AB | -43.17 Million SEK | 156.599% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 113.518% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 242.926% |
| Nanologica AB (publ) | -69.96 Million SEK | 134.926% |
| SynAct Pharma AB | -224.49 Million SEK | 110.884% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 155.313% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 202.007% |
| LIDDS AB (publ) | -40.67 Million SEK | 160.075% |
| Lipum AB (publ) | -37.25 Million SEK | 165.59% |
| BioInvent International AB (publ) | -369.94 Million SEK | 106.605% |
| Alzinova AB (publ) | -16.52 Million SEK | 247.894% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 109.641% |
| Pila Pharma AB (publ) | -6.39 Million SEK | 482.2% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 121.234% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 221.332% |
| Simris Alg AB (publ) | -36.63 Million SEK | 166.699% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 116.672% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 107.871% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 122.031% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | 311.266% |